A citation-based method for searching scientific literature

H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
Times Cited: 422



John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer, Akshay S Desai, Mirta Diez, Jaroslaw Drozdz, Andrej Dukát, Junbo Ge, Jonathan G Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta E A Ljungman, Béla Merkely, Jose C Nicolau, Eileen O'Meara, Mark C Petrie, Pham N Vinh, Morten Schou, Sergey Tereshchenko, Subodh Verma, Claes Held, David L DeMets, Kieran F Docherty, Pardeep S Jhund, Olof Bengtsson, Mikaela Sjöstrand, Anna-Maria Langkilde. N Engl J Med 2019
Times Cited: 1406




List of shared articles



Times cited


SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
12

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
15

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
6

The role of sodium glucose co-transporter inhibitors in heart failure prevention.
Vishnu Garla, Angela Subauste, Javed Butler, Lillian F Lien. J Diabetes Complications 2021
0

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.
Rosalie A Scholtes, Michaël J B van Baar, Megan D Kok, Petter Bjornstad, David Z I Cherney, Jaap A Joles, Daniël H van Raalte. Nephrology (Carlton) 2021
2


Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Mikhail Kosiborod, Otavio Berwanger, Gary G Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Ali Javaheri, Philip Ambery, Samvel B Gasparyan,[...]. Diabetes Obes Metab 2021
14

Estimated plasma volume status in heart failure: clinical implications and future directions.
Masatake Kobayashi, Nicolas Girerd, Kevin Duarte, Tahar Chouihed, Taishiro Chikamori, Bertram Pitt, Faiez Zannad, Patrick Rossignol. Clin Res Cardiol 2021
3



SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6

Effect of dapagliflozin on anaemia in DAPA-HF.
Kieran F Docherty, James P Curtain, Inder S Anand, Olof Bengtsson, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski,[...]. Eur J Heart Fail 2021
5

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
2

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
2

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
9

Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku,[...]. Diabetes Obes Metab 2021
1


Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure.
Flávio A Borges-Júnior, Danúbia Silva Dos Santos, Acaris Benetti, Juliano Z Polidoro, Aline C T Wisnivesky, Renato O Crajoinas, Ednei L Antônio, Leonardo Jensen, Bruno Caramelli, Gerhard Malnic,[...]. J Am Soc Nephrol 2021
4

Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
1

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Elisabetta Moscarella, Felice Gragnano, Teresa Salvatore, Luca Rinaldi,[...]. Int J Mol Sci 2021
3

An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.
Taichi Minami, Akiko Kameda, Yasuo Terauchi. Expert Opin Pharmacother 2021
0

Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK.
Marine Angé, Julien De Poortere, Audrey Ginion, Sylvain Battault, Mélanie Dechamps, Giulio G Muccioli, Martin Roumain, Johann Morelle, Sébastien Druart, Thomas Mathivet,[...]. Sci Rep 2021
2


Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis.
Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile. Adv Ther 2021
0

Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
Victor Chien-Chia Wu, Yan-Rong Li, Chao-Yung Wang. Int J Mol Sci 2021
0

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
Petter Bjornstad, Peter J Greasley, David C Wheeler, Glenn M Chertow, Anna Maria Langkilde, Hiddo J L Heerspink, DaniëL H Van Raalte. J Card Fail 2021
2

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure.
Masaki Nakagaito, Teruhiko Imamura, Shuji Joho, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa. BMC Cardiovasc Disord 2021
0

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mikhail N Kosiborod, Russell Esterline, Remo H M Furtado, Jan Oscarsson, Samvel B Gasparyan, Gary G Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Vijay Chopra,[...]. Lancet Diabetes Endocrinol 2021
9

Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease.
Minyoung Oh, Joon Ho Choi, Seon-Ok Kim, Pil Hyung Lee, Jung-Min Ahn, Seung-Whan Lee, Dae Hyuk Moon, Cheol Whan Lee. Nucl Med Commun 2021
0

Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial.
Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada,[...]. J Card Fail 2021
0

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
0


SGLT2 inhibitors in heart failure with reduced ejection fraction.
Uday Sankar Das, Aritra Paul, Suvro Banerjee. Egypt Heart J 2021
0


The tubular hypothesis of nephron filtration and diabetic kidney disease.
Volker Vallon, Scott C Thomson. Nat Rev Nephrol 2020
49

Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
16